Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy
These include: Severe headaches , particularly if sudden-onset or different from usual patterns Visual disturbances such as blurred vision or seeing spots Chest pain or pressure , which may indicate cardiovascular complications (call 911) Shortness of breath or difficulty breathing, especially with exertion (call 911 if severe) Neurological symptoms including facial drooping, arm weakness, speech difficulties (call 911) Severe dizziness or lightheadedness , particularly upon standing (suggesting hypotension) Nosebleeds that are difficult to control Confusion or difficulty concentrating Patients should also promptly report semaglutide-specific concerns that may require immediate evaluation: Severe, persistent abdominal pain (possible pancreatitis) Right upper quadrant pain, fever, or yellowing of skin/eyes (possible gallbladder disease) Signs of allergic reaction including rash, swelling, or difficulty breathing New or worsening vision problems (potential diabetic retinopathy complications) Persistent nausea, vomiting, or diarrhea can lead to dehydration, electrolyte imbalances, and secondary blood pressure changes
Temperature Matters Injecting medication at the proper temperature can relieve pain
Several candidates are advancing through clinical development, including orforglipron, currently in Phase III trials for obesity and type 2 diabetes
What to Expect Patients may begin to notice weight loss within the first few weeks of treatment, with more significant results over several months
It says the provider should assess these and set a ceiling aligned with tolerability and clinical goals
US$ 25.52
US$ 27.89
US$ 27.72
US$ 23.53
US$ 24.94
US$ 29.88
US$ 23.37
US$ 29.51
US$ 27.51
US$ 27.77
